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Abstract The domesticated horse represents substantial
value for the related sports and recreational fields, and holds
enormous potential as a model for a range of medical
conditions commonly found in humans. Most notable of these
are injuries to muscles, tendons, ligaments and joints. Induced
pluripotent stem (iPS) cells have sparked tremendous hopes
for future regenerative therapies of conditions that today are
not possible to cure. Equine iPS (EiPS) cells, in addition to
bringing promises to the veterinary field, open up the
opportunity to utilize horses for the validation of stem cell
based therapies before moving into the human clinical setting.
Inthisstudy, we report the generation of iPS cells from equine
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DOI 10.1007/s12015-011-9239-5fibroblasts using a piggyBac (PB) transposon-based method
to deliver transgenes containing the reprogramming factors
Oct4, Sox2, Klf4 and c-Myc, expressed in a temporally
regulated fashion. The established iPS cell lines express
hallmark pluripotency markers, display a stable karyotype
even during long-term culture, and readily form complex
teratomas containing all three embryonic germ layer derived
tissues upon in vivo grafting into immunocompromised mice.
Our EiPS cell lines hold the promise to enable the
development of a whole new range of stem cell-based
regenerative therapies in veterinary medicine, as well as aid
the development of preclinical models for human applica-
tions. EiPS cell could also potentially be used to revive
recently extinct or currently threatened equine species.
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Introduction
The establishment of mouse Embryonic Stem (ES) cells
30 years ago [1, 2] gave rise to an unprecedented expansion
of the field of genetics based on the mouse as a model
organism. Soon after, a large effort was launched to find the
equivalent tool for other species as well. Discouraging as it
may be, the establishment of ES cells from many other
species has been tried and has failed for a long time. Only
very recently, as we have gained a deeper understanding of
signaling pathways crucial for maintaining embryonic cells
in the pluripotent state [3], has the establishment of rat
embryonic stem cells been successful [4, 5]. Attempts to
derive equine ES cells face formidable challenges due to
the difficulty and costs associated with recovering the
needed embryos. Earlier, however, two groups have
reported the derivation of equine ES-like cell lines [6, 7],
but these did not give rise to teratomas when transplanted
into immune deficient mice. Hence their genuine pluripo-
tent state is uncertain.
When the first successful derivation attempts of iPS cells
were reported in the mouse [8, 9] and later in the human [10,
11], huge hopes arose for using these as superior alternatives
for ES cells in future cell-based therapies. Indeed, this field
is developing with a tremendous speed, and to date, iPS cells
have successfully been established from several species such
as rhesus monkey [12], rat [13], dog [14], pig [15, 16],
marmoset [17] and rabbit [18]. The derivation of equine iPS
(EiPS) cells has however not yet been reported.
The horse represents a tremendous value both as a sport
and companion animal, and as an excellent model for
certain human diseases. Bone fracture is a common and
very serious injury in these large animals as they respond
poorly to standard treatment used successfully in other
species (including human). Casting and long-term immobi-
lization, for example, is usually not possible or is
accompanied by high risks of devastating secondary
complications. Damaged cartilage, tendons and ligaments
have a poor capacity to heal not only in horses but in other
species as well. Recently, therapeutic approaches using
autologous mesenchymal stem cell (MSC) grafting have
been developed in the horse [19, 20] and reviewed by
Frisbie [21]. While equine MSCs have been shown to
improve the early healing response in articular cartilage
lesions, they do not enhance long-term tissue repair over
that of controls [22]. The use of pluripotent stem cells may
circumvent such issues, as these cells cannot only be
expanded to large quantities in vitro, but they can also be
directed to differentiate into a vast array of specific
progenitor or terminally differentiated cell types. Evidence
of success using such cell-based therapies has recently
been reported [23]. These authors engineered tendon
grafts that effectively repaired injured Achilles tendons
in mice. Their study provided clear evidence that
pluripotent stem cells indeed can be used to treat
orthopedic injuries successfully.
Initially, somatic cell reprogramming to a pluripotent
state was achieved by transducing mouse fibroblasts
through viral vectors carrying the Oct4, Klf4, cMyc and
Sox2 transgenes [9]. To avoid the apparent drawbacks of
the viral system, alternative methods have recently been
developed [24–27]. We have previously reported the use of
the piggyBac (PB) transposons— as a transgene delivery—
combined with tetracycline inducible system for efficient
generation of mouse and human iPS cells [28].
In the present study, we report the establishment of
equine iPS (EiPS) cell lines using the same combination of
PB transposon and tetracycline inducible system, with the
addition of a green fluorescent protein (GFP) marker. Our
EiPS cell lines exhibit properties of pluripotency such as
alkaline phosphatase activity, expression of Oct4, Nanog,
SSEA1, SSEA4, TRA-1-60 and TRA-1-81, and they
display morphology similar to iPS cells from other species.
Furthermore, these lines can be propagated for extended
time periods in vitro without loosing a normal diploid
karyotype, and most importantly, they are capable of
forming teratomas containing tissues representing all three
germ layers; ectodermal, mesodermal and endodermal.
Materials and Methods
Preparation of Equine Fetal Fibroblast (EFF) Cells
Viable fetuses were obtained from a local slaughterhouse
in compliance with the guidelines of the Canadian
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calculated by measuring crown-rump length and estimat-
ed to day 55 of gestation. Skin was dissected from
equine fetuses and exposed to a 5 mg/ml collagenase I
(Sigma #C0130) solution in DMEM for 3 h at 37°C.
After dissociation, cells from each fetus were washed
twice in fresh DMEM with 10% FBS, plated, cultured,
and passaged once to obtain first passage equine fetal
fibroblasts (EFFs). EFF stocks were frozen in DMEM
with 10% FBS and 10% DMSO.
Cell Culture
Equine fetal fibroblasts were maintained in DMEM High
Glucose (Invitrogen 11960–044) supplemented with 2 mM
GlutaMax™ (Invitrogen # 35050), 0.1 mM Non-essential
amino acids (Invitrogen # 11140), 0.1 mM Betamercaptoe-
thanol (Sigma M7522), 1 mM Sodium Pyruvate (Invitrogen
#11360-070), 50 U/ml Penicillin/Streptomycin (Invitrogen
#15070) and 15% fetal bovine serum (HyClone). Culture
media for EiPS cells was the same as above, supplemented
with 1000U/ml leukemia inhibitory factor (LIF; Millipore
#ESGRO), 10 ng/ml bFGF (Peprotech #100-18B), 1.5 μg/ml
Doxycycline(Sigma#D9891)(unlessotherwisestated),3μM
GSKinhibitor (StemGent #CHIR99021),0.5 MMEKinhibitor
(StemGent #PD0325901), 2.5 μM TGF inhibitor (StemGent
#A83-01) and Thiazovivin (StemGent #Thiazovivin). From
day 8of the reprogrammingprocess until thethirdpassage(app
day 30) the media was also supplemented with 25 μMA L K
receptor inhibitor (StemGent #SB431542).
Plasmid Construction
The PB-TET-MKOS and PB-CAG-rtTA plasmids were
constructed as previously described [28]. The transposase
expression vector (pCyL43 PBase) [28] was obtained from
Sanger (http://www.sanger.ac.uk/technology/clonerequests).
PB-GFP was generated by replacing the NheI (polished)
HindIII excised PGK-neo cassette from PB-neo [28] with a
SalI (polished) HindIII fragment composed of the CAG
promoter, GFP coding region, and rabbit beta globin
polyadenylation signal.
Transfection
EFFs were transfected with the Neon electroporation device
(Invitrogen) according to the manufacturers instruction,
using preset program 14. For each electroporation in 10 μl
tips, 5×10
4 cells were used with a total of 1 μg mixed
DNA. The DNA mixture consisted of equal weight ratios of
PB-TET-MKOS, PB-CAG-rtTA, PB-CAG-GFP and
pCyL43. Cells were seeded at a density of 5×10
4 cells
per well of a 9.6 cm
2 surface area.
Establishment of EiPS Cell Lines
Colonies were picked mechanically on day 17–22 post-
transfection without any passaging of the cells prior to
picking. The first passages used mechanical dissociation.
From the third passage onward, the lines were propa-
gated enzymatically with TrypLE Select (Invitrogen
#12563), cultured on mitomycin inactivated feeder
layers consisting of 50% mouse embryonic fibroblasts
isolated from E14.5 embryos with standard procedure
(MEFs) and 50% EFF. The cells were passaged every 2–
3 days at a 1:4 ratio. At the appropriate level of
expansion, the cells were cryopreserved in 90% FBS
and 10% DMSO.
AP and LacZ Staining
Alkaline Phosphatase staining was performed on cells
grown in 4-well tissue culture plates. The cells were
washed once with DPBS and stained with Vector laborato-
ries AP staining kit according to the manufacturers
instructions. For LacZ staining, adherent cultures were
washed once in DPBS and fixed for 10 min in 0.02%
glutaraldehyde (Sigma #D6257) in DPBS. The cultures
were then washed 3 times in DPBS and stained overnight at
37°C in the dark in the following staining solution: 1 mg/
mL X-Gal in N,N-dimethylformamide, 5 mM K4Fe(CN)6
and 5 mM K3Fe(CN)6 (all components from Sigma).
Southern Blotting
To detect the integration site and copy number of the
reprogramming transgenes, ten micrograms of genomic
DNA was digested with BamHI overnight, resolved by gel
electrophoresis, and transferred to Hybond N+ membrane
(GE Healthcare #RPN303B). A neo probe PCR fragment
prepared with Amersham Rediprime™ II DNA Labeling
System (GE Healthcare # RPN1633) was used for
hybridization. The detection of the rtTA transgene was
done the same way, except that the genomic DNA was cut
with HindIII and an rtTA probe was used.
Karyotyping
EiPS cells were grown on 60 mm diameter tissue culture
dishes in the described medium and on fibroblast feeder
layers until semi-confluent. Following enzymatic dissocia-
tion, the cells were re-suspended in culture media,
centrifuged, washed once in DPBS, centrifuged again and
re-suspended in 1 ml DPBS in a 15 ml conical tube. 10 ml
of 0.8% sodium citrate in H2O was added slowly, the tube
was inverted 3 times and incubated at 37°C for 30 min.
Fixative (1 ml of 1:3 acetic acid/methanol) was added and
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2000 rpm for 2 min. The supernatant was decanted leaving
approximately 1 ml behind, and the tube flicked to re-
suspend the cells. Fixative was added slowly while gently
vortexing the tube, and the centrifugation and decanting
step was repeated. The cell suspension was moved to a
1.5 ml micro-centrifuge tube and the fixation/washing step
repeated two more times. Chromosome spreads were
prepared by dropping 20 μl cell suspension onto cold
ultra-clean microscope slides placed in a warm and humid
atmosphere. After 5 minutes drying at 56°C, the slides were
mounted with Vectashield mounting medium with DAPI
(Vector lab #1200).
RT-PCR
RNA was collected from cells grown in 60 mm tissue
culture plates by brief enzymatic dissociation, re-
suspension with culture media, centrifugation, and re-
suspension in Trizol (Invitrogen #15596-026). RNA was
extracted by isopropanol and purified with RNeasy Mini kit
(Qiagen #74104) following manufacturer’s protocol. Re-
verse transcription was performed using Quanti Tect
Reverse Transcription kit (Qiagen #205313) with RT
primers Mix in the kit. The reaction was performed at 42°
C for 60 min. For all samples, a negative RT was used as a
control, consisting of an RT reaction omitting the reverse
transcriptase. In addition, polymerase chain reaction (PCR)
omitting the cDNA was used as a negative control. The
following RT-PCR primers were used to detect the
expression of equine specific β-actin (forward:
ATGGTGGCAATGGGTCAGAAGGAC, reverse:
CTCTTTGATGTCACGCACGATTTC, amplify 550 bp),
Klf4 (forward: AGGCATCTCCCATTTATATTTA, reverse:
CATGGGGAGAGCTCCTC, amplify 332 bp), Nanog
(forward: TCCTCAATGACAGATTTCAGAGA, reverse:
GAGCACCAGGTCTGACTGTT, amplify 323 bp), Oct4
(forward: GGGACCTCCTAGTGGGTCA, reverse:
TGGCAAATTGCTCGAGGTCT, amplify 318 bp). None
of these primer pairs amplify mouse transcrips.
In Vitro Differentiation
EiPS cells were seeded on non-adherent culture plates
(Corning 3471) at a density of 0.5−1×10
5 cells per 9.6 cm
2
culture area (3 cm dish) in medium consisting of DMEM
High Glucose (Invitrogen 11960–044) supplemented with
2 mM GlutaMax™ (Invitrogen #35050), 0.1 mM Beta-
mercaptoethanol (Sigma #M7522), 50U/ml Penicillin/
Streptomycin (Invitrogen #15070) and 5% fetal bovine
serum (HyClone). After 5 days in suspension, the embryoid
bodies (EBs) were plated in 4-well plates coated with a
1:10 dilution of Matrigel (BD #356234) in DPBS.
Immunocytochemistry
Cells grown in 4-well tissue culture plates or on coverslips
were washed twice with DPBS (Invitrogen) and fixed with
3.7% paraformaldehyde solution for 10 min. After three
times washing with DPBS, the cells were permeabilized
with 1% triton for 10 min and blocked 30 min with 5%
normal goat serum (Jackson ImmunoResearch) in DPBS.
The cells were then incubated overnight at 4°C with the
following primary anti-mouse or anti-human antibodies; (i)
anti-Nanog (Reprocell #RCAB0002P-F), (ii) anti-Oct4
(Santa Cruz #sc-5279), (iii) anti-SSEA1 (Stemgent #09-
0005), (vi) anti-SSEA4 (Stemgent #09-0006), (v) anti-TRA-
1-60 (Stemgent #09-0009), (vi) anti-TRA-1-81 (Stemgent
#09-0011). After several washes in DPBS, cells were
incubated for 45–120 min at room temperature with Cy3,
Cy5, FITC or or Allexa 488 conjugated secondary anti-
bodies (Jackson ImmunoResearch or Molecular Probes).
For control experiments, the primary antibody was omitted
or replaced by pre-immune serum, or we used an isotype-
matched control or purified rabbit IgG.
Teratomas
EiPS cells were harvested by TrypLE Select (Invitrogen
#2563) enzymatic dissociation, and 5×10
6 cells were
resuspended in 100 μl Matrigel diluted 1:3 with DMEM.
The cell suspensions were injected subcutaneously into the
dorsal flanks of NOD/SCID (NOD.CB17-Prkdc-scid/J,
Jackson Laboratories) mice. The mice were housed a
specific pathogen free (SPF) condition and the care of the
animals was in accordance with institutional guidelines
(Toronto Centre for Phenogenomics, Toronto, Ontario,
Canada). The mice were given doxycycline by feeding
them doxycycline supplemented food pellets (200 mg/kg,
Bioserv cat # S3888) for 4 weeks to aid the survival and
engraftment of the iPS cells. Three to four months after
injection, teratomas were dissected, fixed overnight in 10%
buffered formalin phosphate and embedded in paraffin.
Sections were stained with hematoxylin and eosin.
Imaging
Bright field and fluorescence images of live cells and EBs
were acquired on a Leica DMIL inverted microscope
equipped with a QImaging Retica 12-bit color digital
camera and OpenLab software. Chromosome spreads were
imaged on a Leica DMR inverted microscope equipped
with a 100x oil immersion lens, a Leica DC300F digital
camera and QWin software. Immunofluorescent signals
were visualized and digital images were obtained by using
a Zeiss LSM 510 confocal microscope equipped with two
photon, argon and helium–neon lasers (Zeiss). Confocal
696 Stem Cell Rev and Rep (2011) 7:693–702imaging was also performed using an Olympus FV1000
laser-scanning confocal microscope. The acquisition of
images was done with Fluoview 1000 software and the
time of acquisition of fluorescent samples was 10 micro-
seconds with a resolution of 1024 X 1024 pixels. Kalman
filter was applied to remove noise background. The
acquired images were then exported as TIFF files and
processed using Olympus Fluoview software FV10-ASW
(Olympus Canada, Markham, ON, Canada).
Results
Generation and in Vitro Characterization of EiPS Cell Lines
We set out to derive iPS cells from equine fetal fibroblasts
using our previously established PB transposon-based
system to deliver the reprogramming factors [28, 29]. The
main feature of this approach lies in a vector in which c-
Myc, Klf4, Oct4 and Sox2 (MKOS) are linked by 2A
peptide sequences (i.e. MKOS) [29]. In order to gain
temporal control over the reprogramming process, the four
factors are placed under the transcriptional control of the
tetO2 promoter (PB-TET-MKOS) (Fig. 1a1). An IRES-
ßgeo cassette following MKOS renders the cells both
neomycin resistant as well as LacZ positive upon Dox
treatment. The tetracycline reverse transactivator (PB-CAG-
rtTA) (Fig. 1a2), a vector containing a constitutive GFP
expression cassette (PB-CAG-GFP) (Fig. 1a3), as well as a
circular transient PB transposase (pCyL43 PBase) [28]
expression vector (Fig. 1a4) were all co-electroporated with
the PB-TET-MKOS plasmid. We electroporated passage 3
fibroblasts (Fig. 1b1) and plated them at a density of
approximately 1.5×10
5 cells per 30 mm culture dish. By
comparing the number of live cells in transfected versus
non-transfected cells on the day following electroporation,
we estimated the survival rate to be 75%. We estimated the
transfection efficiency to 46% (data not shown) from the
ratio of GFP positive cells.
The reprogramming process was induced by adding Dox
to the culture medium 2 days after transfection. At this
time, the media was also supplemented with LIF and bFGF,
a GSK-inhibitor (CHIR99021), TGFbeta-inhibitor (A8301),
MEK-inhibitor (PD0325901) cocktail [3] and Thiazovivin
[30]. On day 8 post-transfection, the ALK receptor inhibitor
SB431542 was added to the media as well [30]. This
compound was maintained in the media only from day 8 to
30, while the other inhibitors and Dox were added to the
media at all times. On day 14 post-transfection, focal areas
of increased proliferation could be observed. Within these
regions, the cells took on a more rounded and densely
growing morphology. Three to 4 days later, many of these
areas developed into clearly defined colonies (Fig. 1b2),
which were then picked on day 17–22 post-transfection.
After an initial three mechanical passages, the cells could
be enzymatically dissociated with TrypLE Select and split
at a rate of 1:4 every 2–3 days. The cells survived
cryopreservation and thawing, and we were able to expand
them to large quantities.
Initially, we kept the cultures growing on a feeder
layer consisting of MEFs. When we placed the EiPS
cells on a EFFs feeder layer, the growth rate slowed
down but the colonies took on a denser and more well
defined appearance (data not shown). By mixing MEFs
and EFFs at a 1:1 ratio, we obtained what seemed to be
the most advantageous conditions for EiPS cells. On this
feeder composition, the colonies grow at the same rate as
w h e ng r o w no nM E F s ,a n dt h e ym a i n t a i nd e n s ec o l o n y
morphology.
Using three independent fetal fibroblast sources, we
successfully established a total of 25 EiPS cell lines. The
reprogramming efficiency was estimated to 0.028% by
dividing the number of transfected (GFP
+) cells surviving
electroporation by the number of colonies found on each
plate (data not shown). This rate is similar to those obtained
when reprogramming human and mouse fibroblasts with
the same transfection system [28].
In Vitro Characterization of EiPS Cell Lines
The EiPS colonies exhibited morphology similar to human
iPS cells with monolayer organization, well-defined edges
(Fig. 1b3) and a high nuclear to cytoplasm ratio (Fig. 1b4).
As expected, the lines were positive for LacZ expression
while the media was supplemented with Dox, proving that
the transgenes were active (Fig. 1b5). Alkaline phosphatase
activity could also clearly be detected (Fig. 1b6).
Co-electroporation of the PB-CAG-GFP vector resulted in
approximately half of the resulting EiPS cell lines being GFP
+
(data not shown). For further analysis, we focused on those
lines that strongly expressed this fluorescent marker (Fig. 1c).
Southern blotting using probes specific both for the
combined reprogramming factors (Fig. 2a1) as well as for
the rtTA transgene (Fig. 2a2) revealed that most lines had a
relatively low number of MKOS integrations and a higher
number of integrations of the PB-CAG-rtTA transposon.
We then examined the chromosome number integrity in
13 EiPS cell lines. After preparing mitotic chromosome
spreads (Fig. 2b), we counted the chromosomes from 30–
50 cells for each line. Some lines exhibited a low ratio of
euploid cells, but the majority possessed an euploid count
in at least 80% of the cells (Fig. 2c). We followed the
chromosome count stability of three EiPS cell lines over
increased passage numbers and could confirm that the
euploid rate was only slightly decreased at least up until
passage number 26 (data not shown).
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expression of the key pluripotency markers Nanog, SSEA1,
SSEA4,Tra-1-60andTra-1-81(Fig. 3a). In addition, RT-PCR
using horse-specific primers, confirmed a robust expression
of equine endogenous Oct4, Nanog and Klf4 (Fig. 3b).
Next,wecreatedembryoidbodies(EBs)fromEiPScellsto
assess their developmental potential in vitro.A f t e r4d a y so f
suspension culture in media lacking LIF, FGF, inhibitors and
Dox, the cells formed EBs (Fig. 4a) that already on day 4
developed fluid filled cysts (Fig 4a arrow). This cyst
formation is unusually early and may indicate an accelerated
differentiation of EiPS cells compared to mouse and human
pluripotent stem cells. This notion was further supported by
the observation that the horse EBs tended not to aggregate to
each other at higher densities and they did not attach to
standard tissue culture plastic or a variety of substrates such
as Laminin, Collagen or Fibronectin. Matrigel-coated tissue
culture surface, however, allowed day 6 EBs to attach and
expand into a variety of cell types. Unfortunately, due to the
lack of suitable antibodies raised against equine cells [31],
we were not able to perform immunocytochemical analyses
of these differentiated cultures. To compensate for this
shortcoming, we focused on characterizing the pluripotency
of our EiPS cell lines using in vivo assays.
3’ PB-ITR 5’ PB-ITR TetO MKOS IRES β-geo
5’ PB-ITR 3’ PB-ITR CAG rtTA
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1
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PB-CAG-rtTA
PB-CAG-GFP
pCyL43 PBase
Bright field GFP Merge C
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Fig. 1 EiPS cell derivation. (a).
The reprogramming vector set.
1. PB-TET-MKOS vector con-
taining the tetracycline inducible
reprogramming factors (c-Myc,
Klf4, Oct4 and Sox2) and an
IRES linked ßgeo. 2. PB-CAG-
rtTA vector providing expres-
sion of the tetracycline reverse
transactivator. 3. PB-CAG-GFP
vector allowing expression of
the Enhanced Green Fluorescent
Protein. 4. pCyL43-PBase pig-
gyBac transposase expression
vector. (b). Morphology of
equine cells in vitro. 1. Equine
fetal fibroblasts. 2. Primary
EiPS colony. 3. Colonies during
expansion using enzymatic pas-
saging. 4. High magnification
photograph of EiPS cell show-
ing high nucleus to cytoplasm
ratio (arrow). 5. LacZ staining
reveals transgene expression. 6.
EiPS cells are alkaline phospha-
tase positive. (c). GFP expres-
sion in EiPS colonies. Scale bars
50 μm
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We continued our in vivo characteization by implanting our
EiPS cells into immunocompromised mice. The presence of
GFP expression was strong also after differentiation into
large teratomas (Fig 4b). Four months after implantation,
we were able to harvest teratomas that contained cell types
derived from all three embryonic germ layers, indicating
that our EiPS cell lines are truly pluripotent cells (Fig. 4c).
Most importantly, these tumors did not show any signs of
malignancy. They were very well defined and did not
produce any metastatic tumors (data not shown).
Discussion
We report here the successful establishment of equine iPS
(EiPS) cells. Building on our previous experience, we chose
the PB transposon system to deliver the tetracycline inducible
reprogramming transgenes c-Myc, Klf4, Oct4 and Sox2 into
equine fetal fibroblasts (EFFs). Based on Southern blotting
analysis, we could determine that the number of integration
sites for each transgene was relatively low, in most cases
between 1 and 4 (Fig 2a). The higher copy number for the
rtTA transposon may be due to a higher molecular ratio upon
transfection as equal weights of plasmid were used despite
the smaller size of PB-CAG-rtTA (7016 bp) as compared to
PB-TET-MKOS (14216 bp). As evident by the Southern
blotting analysis for PB-TET-MKOS and PB-CAG-rtTA
transposons, the lines H2-D and H2-F are genetically
identical (Fig. 2a) and therefore most likely the result of
the same reprogramming event.
The characterization of these lines posed a significant
challenge mainly due to the lack of antibodies that are
specific for equine pluripotency markers [31] limiting us to
use those that are raised against mouse or human and by
chance cross-react with the corresponding equine factors.
We attempted to assess the capacity of EiPS cells to
differentiate in vitro by producing EBs that subsequently
were allowed to adhere and grow out under in vitro
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Fig. 2 Genomic and cytogenet-
ic properties of EiPS cell lines.
(a). Southern blotting analysis to
detect integration of the 1. PB-
TET-MKOS and 2. PB-CAG-
rtTA transgenes. Number of in-
tegration sites are indicated at
the bottom of each membrane.
(b). DAPI stained mitotic chro-
mosome spread. (c). Ratio of
cells with normal (euploid)
chromosome counts among
EiPS cell lines
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Fig. 3 In vitro characterization
of the pluripotent state of EiPS
cells.(a). Nanog, SSEA1, SSEA4,
TRA-1-60 and TRA-1-81
detected by fluorescent immuno-
histochemistry. Yellow scale bar
10 μm, white scalebar 20 μm.
(b). Detection of gene expression
of key pluripotency markers using
RT-PCR primers specific for
equine endogenous genes
700 Stem Cell Rev and Rep (2011) 7:693–702differentiation conditions. Suitable antibodies to detect
specific cell lineages in the equine differentiating cells are
unfortunately not available, and this limitation restricted our
ability to characterize the cells by immunocytochemical
assays. The extremely long time it would take to examine
the developmental potential of EiPS cells in vivo through
aggregation with equine embryos places this experiment
beyond the scope of this report. With these challenges is
mind, we decided to perform the next most stringent in vivo
test of pluripotency we did have at hand; formation of
teratomas in immunocompromised mice. Our initial
attempts resulted in very slow growth of the teratomas;
not until 6 months after initial implantation of EiPS cells
did we observe tumor formation. We attributed this finding
to the notion— supported by the unusually rapid in vitro
differentiation of EiPS cells into cystic embryoid bodies—
of an accelerated differentiation of these cells in permissive
environments. To counteract this putative property of the
cells, we fed the recipient mice with doxycycline for
4 weeks to inhibit with the premature final differentiation
of the engrafted iPS cells. We then removed Dox from the
animals diet to let the grafted cells differentiate and form
teratomas. Fully differentiated teratomas with derivatives of
all three germ layers then readily formed within 2 months
after the Dox treatment was stopped.
Efforts have long been ongoing to establish pluripotent
stem cells from horses. Access to such cell lines would not
only be of great value for veterinary medicine, but would
also open up possibilities to use the horse as an excellent
pre-clinical model for future human stem cell-based
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50
C
B A
Fig. 4 Characterization of the
differentiation potential of EiPS
cells. (a). Embryoid bodies
(EBs) that become cystic (white
arrow). (b). Teratoma in situ on
the hind limb of a mouse (arrow
pointing at the tumor), showing
strong GFP expression. (c). Ter-
atoma assay; 1–3, derivatives of
the embryonic endoderm: 1, 2.
Intestine-like structures, black
arrows (1,2), and respiratory
epithelium, black arrow (3). 4–
6, derivatives of the embryonic
mesoderm: Bone, black arrows
(4), cartilage (5), and muscle,
black arrows (6). 7–9, deriva-
tives of the embryonic ecto-
derm: Neuroepithelium, black
arrow (7), glycogeneted epithe-
lium, black arrow (8), and skin
epithelium (black arrows) and
keratin (yellow arrow) (9)
Stem Cell Rev and Rep (2011) 7:693–702 701therapies. We report on the successful derivation of iPS
cells from equine fibroblasts. Our EiPS cell lines display a
pluripotent phenotype based on expression of key markers,
alkaline phosphatase activity, and the formation of complex
teratomas representing all three embryonic germ layers.
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